ElsaLys Biotech

ELSALYS BIOTECH is a specialty pharmaceutical company belonging to the Mediolanum Farmaceutici Spa group, focusing on innovative drugs to address life-threatening rare diseases associated with hematological malignancies. Following strategic acquisitions and targeted development, ELSALYS is building an immunotherapy portfolio centered on niche specialty drugs to meet unmet medical needs. Today, ELSALYS BIOTECH is advancing three proprietary development programs, including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical benefits in Phase 3 trials for an orphan disease with extremely poor prognosis: steroid-resistant acute graft-versus-host disease (GvHD). It is currently benefiting from the French ATU cohort for the treatment of GvHD, corticosteroid-resistant or corticosteroid-dependent grade II-IV.